<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and complications of inflammatory bowel disease in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and complications of inflammatory bowel disease in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and complications of inflammatory bowel disease in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher J Moran, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Athos Bousvaros, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inflammatory bowel disease (IBD) is comprised of two major disorders: Crohn disease (CD) and ulcerative colitis (UC). CD can involve any component of the gastrointestinal tract from the oral cavity to the anus and is characterized by transmural inflammation. It typically involves the ileum, ileum and cecum, or ileum and portions of or the entire colon. UC affects the colon and is characterized by inflammation of the mucosal layer. Mild ileal inflammation (usually histologic, with mild ileal erythema and granularity, or "backwash ileitis") can be seen in UC. The diagnosis and differentiation between UC and CD are based on a critical assessment of clinical features, biochemical studies, endoscopic findings, histology, and luminal imaging. These disorders have distinct pathologic and clinical characteristics but may sometimes be difficult to distinguish in cases without small bowel involvement.</p><p>The peak incidence of IBD occurs in patients between the ages of 15 and 30 years and appears to be rising in the pediatric age group [<a href="#rid1">1-4</a>]. Approximately 20 percent of patients with CD and 12 percent of patients with UC develop their IBD before the age of 20 years [<a href="#rid5">5</a>]. Adults and children with IBD may present with similar clinical features; however, children are at risk for growth failure and delayed puberty due primarily to persistent chronic inflammation. Therefore, in addition to treating the intestinal manifestations of IBD, the treating clinician must monitor and treat the extraintestinal manifestations of IBD, which can be subtle. These include malnutrition, impairment of linear growth, liver inflammation, osteopenia, and mental health issues.</p><p>The clinical manifestations of IBD in children and adolescents are reviewed here. The diagnosis of IBD, including the differentiation between CD and UC, is discussed separately. (See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRESENTING SYMPTOMS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical presentation</strong> – Patients with IBD typically present in late childhood or adolescence with one or several of the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal symptoms</strong> – Patients with ulcerative colitis (UC) usually present with bloody diarrhea, abdominal pain often around bowel movements, and tenesmus. The gastrointestinal manifestations of Crohn disease (CD) can be more subtle, with low-grade abdominal pain, weight loss, lack of appetite, and diarrhea with or without blood. However, the clinical presentations are quite variable, so these features are not sufficient to distinguish between these disorders.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic symptoms</strong> – Fever, fatigue, and anorexia are common at presentation and during flares of disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physical findings</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Gastrointestinal – In UC, the abdominal examination is often normal, though some tenderness may be seen. In CD, the abdominal examination may be normal or abdominal tenderness and/or mass (classically in the right lower quadrant) and perianal disease (fistulae, anal skin tags, or fissures) may be seen. Either CD or UC may have gross or occult blood in stool. Some patients, especially those with CD, may have pubertal delay (Tanner stage less than expected for chronologic age).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Extraintestinal manifestations – Extraintestinal manifestations of IBD include oral ulcerations (aphthous stomatitis), digital clubbing, rash (erythema nodosum or pyoderma gangrenosum), eye inflammation (uveitis), jaundice or hepatomegaly (due to sclerosing cholangitis or hepatitis), or arthritis. (See <a class="local">'Extraintestinal manifestations'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Growth – Growth failure (subnormal gains in height or weight, or weight loss) and/or delayed puberty is a common feature, especially in children with CD. Many children are of normal weight, however, and some may even be overweight at presentation [<a href="#rid6">6</a>]. Thus, obesity or lack of growth failure should not preclude a diagnosis of IBD.</p><p></p><p class="bulletIndent3">Although growth failure is frequently present at the time of diagnosis [<a href="#rid7">7,8</a>], it may not be recognized by the child or family. The earliest and most subtle form of growth failure is a decrease in height velocity, which may be present for months or years before other symptoms are present. This may progress to short stature for age, delayed bone age, and/or pubertal delay. (See <a class="local">'Growth failure'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Very early-onset IBD</strong> – Occasionally, IBD presents during early childhood (&lt;6 years) or even in infancy. These children are somewhat less likely to present with abdominal pain and weight loss and are more likely to present with rectal bleeding (33 percent) compared with those with onset later in childhood [<a href="#rid9">9</a>]. A subset of patients with very early-onset IBD have an underlying genetic defect that affects immune function or disturbs epithelial barrier function, sometimes known as "monogenic IBD." A focused evaluation for such disorders is warranted. (See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Very early-onset inflammatory bowel disease'</a>.)</p><p></p><p class="headingAnchor" id="H1154183876"><span class="h1">GASTROINTESTINAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3170658772"><span class="h2">Ulcerative colitis</span><span class="headingEndMark"> — </span>Ulcerative colitis (UC) is characterized by recurring episodes of inflammation limited to the mucosal layer of the colon. It commonly involves the rectum and may extend proximally in a <strong>continuous</strong> fashion to involve other parts of the colon. In some patients, the disease pattern persists throughout the clinical course. For other patients, the disease extends proximally as disease activity increases.</p><p>For clinical care, it is useful to categorize UC into the following categories  (<a class="graphic graphic_table graphicRef89029" href="/d/graphic/89029.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Ulcerative proctitis – Disease limited to the rectum</p><p class="bulletIndent1"><span class="glyph">●</span>Left-sided disease – Disease that extends from the rectum into the left colon but not proximal to the splenic flexure</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive colitis – Disease that extends from the rectum into the transverse colon but not proximal to the hepatic flexure</p><p class="bulletIndent1"><span class="glyph">●</span>Pancolitis – Disease that extends throughout the colon, including some or all of the cecum</p><p></p><p>UC extends proximally in a continuous pattern, in contrast with the discontinuous pattern sometimes seen in Crohn disease (CD). Mild histologic inflammation in the terminal ileum occasionally occurs in UC (sometimes called "backwash" ileitis), but more severe ileal inflammation, or involvement of other segments of the small bowel, suggests that the patient has CD instead of UC. Occasionally, a patient with UC has focal inflammation around the appendiceal orifice that is not contiguous with disease elsewhere in the colon (a "cecal patch"). (See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Differentiation between Crohn disease and ulcerative colitis'</a>.)</p><p class="headingAnchor" id="H3824914980"><span class="h2">Crohn disease</span></p><p class="headingAnchor" id="H3"><span class="h3">Intestinal disease localization</span><span class="headingEndMark"> — </span>CD can affect the entire gastrointestinal tract and is a progressive condition causing transmural inflammation. In children and adolescents, it can present with involvement of both small bowel and colon (59 percent), colon only (28 percent), or primarily the small bowel (16 percent, usually in the terminal ileum) [<a href="#rid4">4</a>]. CD may be limited to the colon and, in such cases, may be difficult to distinguish from UC. CD that involves the colon is more likely to have a discontinuous pattern ("skip" lesions), involving the rectum and other parts of the gastrointestinal tract, separated by normal segments, whereas UC typically has a continuous pattern throughout the involved segments. The most important clinical features that classify a patient as having CD rather than UC are significant small bowel disease, perianal disease, or presence of granulomas in the gastrointestinal tract on biopsy. While the finding of granulomas on intestinal biopsy has been considered virtually pathognomonic (strongly predictive) for CD, some investigators have suggested that gastric granulomas may also rarely be seen in UC [<a href="#rid10">10</a>].</p><p>A small number of children at presentation have more diffuse small bowel disease, isolated perianal disease, esophageal or gastric disease, or severe orofacial disease. Patients may be classified by age, disease location (ileum only, colon only, ileocolon, or upper gastrointestinal tract), and disease behavior (inflammatory, stricturing, or penetrating). Documenting and monitoring these characteristics and their evolution over time is an important part of clinical care. It is important to note that although disease location and severity may wax and wane during the disease course, the extent and severity of IBD is defined by worst extent and severity experienced by the patient.</p><p>Research studies and registries sometimes use the Paris classification to categorize the location and other clinical features of CD in children  (<a class="graphic graphic_figure graphicRef89025" href="/d/graphic/89025.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef89028" href="/d/graphic/89028.html" rel="external">table 2</a>) [<a href="#rid4">4</a>]. The Paris classification is a modification of the Montreal classification system that is used in adults and includes a clearer definition of earlier-onset IBD and growth delay [<a href="#rid11">11,12</a>]. The Paris classification can also be utilized in clinical practice. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Clinical assessment'</a>.)</p><p class="headingAnchor" id="H22526907"><span class="h3">Intestinal disease complications</span><span class="headingEndMark"> — </span>A substantial proportion of children and adolescents with CD present with or progress to developing intestinal complications, which are an important cause of morbidity. Patients who tend to develop these complications are often categorized as having a stricturing and/or penetrating phenotype, present in approximately 30 percent of pediatric patients and up to 45 percent of adult patients [<a href="#rid13">13,14</a>]. The main risk factors for these complications are a stricturing and/or penetrating phenotype, extensive small bowel disease involvement (over and above small bowel disease only involving the terminal ileum), and longer disease duration [<a href="#rid15">15</a>]. Children diagnosed during adolescence appear to have a higher risk for these complications compared with those diagnosed at a younger age [<a href="#rid16">16</a>]. They are most likely to develop over time in patients with severe or refractory disease but occasionally are a presenting feature. These complications include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fistulae</strong> – Fistulae may develop between the diseased bowel and a variety of adjacent tissues. Fistulae between different segments of the bowel (enteroenteric) may be asymptomatic or may cause symptoms because of malabsorption or small intestinal bacterial overgrowth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fistulae from the bowel to the bladder (enterovesicular) tend to present with recurrent urinary tract infection or a sensation of air in the urine stream (pneumaturia)</p><p class="bulletIndent2"><span class="glyph">•</span>Fistulae from the bowel to the genitalia (enterogenital) tend to present with pain or fecal leakage</p><p class="bulletIndent2"><span class="glyph">•</span>Fistulae from the bowel to the skin (enterocutaneous) are most common in the perianal area and may form subcutaneous abscesses</p><p></p><p class="bulletIndent1">Treatment may include immunomodulators, biologic agents, antibiotics (eg, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>), or total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> with bowel rest. Surgery (intestinal diversion) is used for fistulizing disease that is refractory to treatment. Anti-tumor necrosis factor (anti-TNF) agents (<a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>) are the best-established agents for treating fistulizing disease. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Fistulizing disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized peritonitis</strong> – Localized peritonitis tends to present with fever, chills, leukocytosis, nausea or vomiting, and focal abdominal pain, often in the right lower quadrant. It is caused by a microperforation of the bowel with containment of the resultant infection by surrounding bowel loops. The initial treatment usually consists of broad-spectrum antibiotics and bowel rest. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Localized peritonitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal abscess</strong> – An abscess tends to develop adjacent to actively inflamed bowel loops and may develop further into a fistula. Similar to patients with localized peritonitis, patients with an abdominal abscess tend to present with fever, leukocytosis, and focal abdominal pain, often in the right lower quadrant or pelvis [<a href="#rid15">15</a>]. A high index of suspicion is warranted for patients who are on immunosuppressive therapy, who may present with more subtle symptoms and without fever or leukocytosis. The onset of symptoms may be gradual or sudden.</p><p></p><p class="bulletIndent1">The evaluation includes imaging (ultrasonography, computed tomography [CT], or magnetic resonance imaging [MRI]). Initial treatment consists of antibiotics, typically with percutaneous drainage for abscesses that are &gt;2 cm in diameter, and optimization of CD therapy. Because abdominal abscesses result from bowel perforations (typically in the ileum), surgical resection of the diseased bowel is often needed. In some cases, small abscesses can be managed by optimizing medical management rather than proceeding to surgery. However, we advise caution about extending the use of biologics or other immunosuppressive medications in the presence of an active abscess because of the risk of ongoing leak and infection, in addition to the potential increased risk of surgery in patients after prolonged immunosuppression. (See  <a class="medical medical_review" href="/d/html/86198.html" rel="external">"Surgical management of Crohn disease", section on 'Abscess'</a> and  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Abscess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small bowel obstruction</strong> – Severe disease of the small intestinal lumen, with ulceration and transmural inflammation, tends to lead to stricture formation. Depending on the location and severity, this can cause partial or complete intestinal obstruction, presenting with symptoms of nausea, vomiting, and abdominal pain. A stricture often becomes symptomatic because of superimposed inflammation and spasm, so the obstruction may improve with conservative management, including bowel rest and parenteral glucocorticoids or biologic agents such as <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, which help to decrease any inflammatory component of the obstruction. Acute deterioration (eg, worsening obstruction or bowel ischemia) may require urgent surgery. Elective surgery is frequently required in patients who develop recurrent obstructive episodes from a fibrotic stricture. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Partial small bowel obstruction'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Oral and perianal disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perianal disease</strong> – Perianal abnormalities are common. They are sometimes present at diagnosis and eventually develop in approximately one-third of children with CD [<a href="#rid17">17</a>]. Perianal involvement may be mild (consisting of small skin tags or anal fissures  (<a class="graphic graphic_picture graphicRef121947" href="/d/graphic/121947.html" rel="external">picture 1</a>)) or more severe (abscesses and fistulae). In a series of pediatric patients with CD, 10 percent had perianal fistulas and/or abscesses at the time of diagnosis and one-third of these had persistent perianal disease for more than one year despite treatment [<a href="#rid18">18</a>]. As many as 5 percent of children develop a highly destructive form of perianal disease that is characterized by recurrent perianal abscesses, fistulae involving the genitalia, and development of rectal strictures  (<a class="graphic graphic_picture graphicRef75104" href="/d/graphic/75104.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1">Severe perianal disease may be refractory to medical treatment (including antibiotics, biologic agents such as <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, immunomodulators such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, and exclusive enteral nutrition [<a href="#rid19">19</a>]). <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a> has also been reported to have efficacy in treating perianal fistulae [<a href="#rid20">20</a>]. Surgical options for perianal fistulas include Seton placement or fistulotomy; a minority of patients may require colonic diversion [<a href="#rid17">17,21</a>]. (See  <a class="medical medical_review" href="/d/html/4082.html" rel="external">"Perianal Crohn disease"</a> and  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Exclusive enteral nutrition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral lesions</strong> – Orofacial lesions are reported in 10 to 40 percent of children with CD  (<a class="graphic graphic_picture graphicRef138273" href="/d/graphic/138273.html" rel="external">picture 3</a>) [<a href="#rid22">22,23</a>]. (See <a class="local">'Mouth'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated orofacial and perianal findings</strong> – Isolated orofacial and perianal inflammation can occur in the absence of bowel disease or may precede the development of bowel disease by several years [<a href="#rid24">24</a>]. In these patients, a biopsy of the inflamed lips, buccal mucosa, or perianal skin tags may demonstrate granulomas.</p><p></p><p class="headingAnchor" id="H21768401"><span class="h3">Esophageal and gastric disease</span><span class="headingEndMark"> — </span>Esophageal and gastric disease are present in approximately 30 percent of patients with CD and are more common among those with perianal disease or more severe ileocolonic disease [<a href="#rid4">4,25</a>]. In case series of children and adolescents with CD, approximately 10 percent had visible lesions on endoscopy (ulcers, erosions, and edematous nodules), 20 percent had microscopic evidence of CD, and 40 percent had nonspecific microscopic signs of inflammation [<a href="#rid25">25,26</a>]. Approximately one-third of patients with esophageal CD report esophageal symptoms [<a href="#rid25">25,26</a>]. Isolated esophageal CD is rare, and concurrent gastric and duodenal involvement is common. As a result, performing upper endoscopy is an essential part of the evaluation of CD and especially for patients with upper gastrointestinal symptoms, severe CD, or perianal disease. (See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a>.)</p><p>Symptomatic esophageal and gastric CD is treated with acid-suppressing medications, in addition to vigorous treatment for the underlying CD using immunosuppressive medications and/or enteral nutrition. Optimal treatment and natural history of esophageal CD have not been well studied. We generally do not use acid-suppressing medications for asymptomatic patients, due to concerns that these medications may increase the risk for <em>Clostridioides</em> <em>difficile</em> infection. (See  <a class="medical medical_review" href="/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Clostridioides difficile and other enteric infections'</a>.)</p><p>Mild nonspecific abnormalities of the upper gastrointestinal tract are common in both UC and CD, but significant ulceration of the esophagus, stomach, or duodenum is inconsistent with UC. Mild gastritis with histologic inflammation can be seen in either CD or UC. However, severe gastric disease or granulomas in a patient with colitis suggests the diagnosis of CD. Esophagitis with aphthae also may be seen in CD. Eosinophilic esophagitis has been reported in a subset of patients with either UC or CD [<a href="#rid27">27,28</a>], but this may be the result of case finding in a referral population [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Differentiation between Crohn disease and ulcerative colitis'</a>.)</p><p class="headingAnchor" id="H372147141"><span class="h1">GROWTH AND NUTRITION</span></p><p class="headingAnchor" id="H372147147"><span class="h2">Growth failure</span><span class="headingEndMark"> — </span>Growth failure is seen in 10 to 30 percent of children with Crohn disease (CD) [<a href="#rid7">7,8,15,30-33</a>] and 5 to 10 percent of children with ulcerative colitis (UC) [<a href="#rid7">7</a>]. Growth failure can be defined dynamically as a fall in the height percentile of more than 0.3 standard deviations/year, a height velocity of less than 5 cm/year, or a decrease in the height velocity of more than or equal to 2 cm compared with the previous year, during early to mid-puberty. To assess most accurately for growth failure, a child's growth rate should be compared with expected growth rates for age  (<a class="graphic graphic_figure graphicRef70382" href="/d/graphic/70382.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature"</a>.)</p><p>One study using these definitions found that approximately 30 percent of children with CD had growth failure [<a href="#rid7">7</a>]. In another report, approximately 50 percent of children with untreated CD had short stature or evidence of diminished height velocity [<a href="#rid8">8</a>]. The diminished height velocity may occur before the onset of symptoms and may be unrecognized by the child's caregivers, but it can be detected by plotting a patient's height and weight on the appropriate growth chart. Delays in IBD diagnosis are associated with growth delays that can persist well beyond one year after diagnosis [<a href="#rid34">34</a>]. Delayed sexual maturation (pubertal delay) commonly accompanies growth failure in adolescents.</p><p>The causes, assessment, and management of growth failure and poor weight gain in children with IBD are discussed in a separate topic review. Timely and effective therapy that reduces inflammation may help reverse growth failure in children. Treatment of the IBD with exclusive enteral nutrition may be particularly helpful for this group of patients. (See  <a class="medical medical_review" href="/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Nutritional therapy'</a>.)</p><p class="headingAnchor" id="H372147181"><span class="h2">Vitamin and mineral deficiencies</span><span class="headingEndMark"> — </span>The risk for vitamin and mineral deficiencies in IBD depends upon the type of IBD (CD versus UC), disease location, and disease activity. Causes of vitamin deficiencies in this population include malabsorption and limited intake (perhaps driven by altered dietary habits due to IBD symptoms).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD</strong> – A number of vitamin and mineral deficiencies have been associated with CD. These include deficiencies in vitamins A, D, and E; zinc; and vitamin B12 (the latter is most common in patients with ileal CD). Vitamin D deficiency appears to be the most common deficiency and may contribute to osteopenia and increased fracture risk, which are also exacerbated by disease-related inflammatory activity. In general, patients with active disease have a higher prevalence of deficiencies of vitamin D and other micronutrients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UC</strong> – Vitamin and mineral deficiencies are less common in children with UC, except for those with uncontrolled acute severe colitis. An exception is that patients who have had colectomy with ileal pouch anal anastomosis may be at risk for vitamin B12 deficiency because of changes in intestinal morphology in the terminal ileum.</p><p></p><p>Details about the risks, monitoring, and management are discussed separately. (See  <a class="medical medical_review" href="/d/html/5887.html" rel="external">"Vitamin and mineral deficiencies in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Bone mineral density'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">EXTRAINTESTINAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Extraintestinal conditions associated with IBD may be present at diagnosis or develop later in the disease course [<a href="#rid35">35</a>]. These may involve the skin, joints, hepatobiliary tract, eye, kidney (ie, stones), and (rarely) pancreas and respiratory systems, as well as risks for venous thrombosis  (<a class="graphic graphic_table graphicRef81867 graphicRef88092" href="/d/graphic/81867.html" rel="external">table 3A-B</a>). These disorders appear idiosyncratically in some patients and not others but are more often associated with colonic disease; they do not consistently correlate with the degree of intestinal inflammation.</p><p class="headingAnchor" id="H258643409"><span class="h2">Skin</span><span class="headingEndMark"> — </span>IBD is associated with several different dermatologic disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema nodosum</strong> is characterized by painful, raised, red lesions 1 to 3 cm in diameter and seen most commonly on the shins  (<a class="graphic graphic_picture graphicRef80056 graphicRef76621" href="/d/graphic/80056.html" rel="external">picture 4A-B</a>). It is a presenting feature in approximately 5 percent of children with IBD and typically resolves rapidly when IBD therapy is instituted; it is seen more often in patients with Crohn disease (CD) than ulcerative colitis (UC) [<a href="#rid36">36-38</a>]. Erythema nodosum also may be caused by disorders other than IBD, including infections (eg, group A <em>Streptococcus</em>, tuberculosis), medications (eg, penicillin, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>), autoimmune disease (eg, rheumatoid arthritis, lupus), and malignancy. (See  <a class="medical medical_review" href="/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Erythema nodosum'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pyoderma gangrenosum</strong>, a severe ulcerating rash that responds to immunosuppression, is rare in children and is seen more often in patients with longstanding UC than in patients with CD. However, it has been described in an infant with CD [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Pyoderma gangrenosum'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metastatic CD</strong> is a rare dermatologic manifestation characterized by erythema, edema, ulcerating nodules, and violaceous plaques, sometimes in a linear or "knifelike" pattern  (<a class="graphic graphic_picture graphicRef94887" href="/d/graphic/94887.html" rel="external">picture 5</a> and <a class="graphic graphic_picture graphicRef103584" href="/d/graphic/103584.html" rel="external">picture 6</a>). Most cases in children are in the genital area [<a href="#rid40">40,41</a>]. Such patients may present to the urologist with swelling of the penis and scrotum and be given the diagnosis of "granulomatous lymphangitis" [<a href="#rid42">42</a>]. The lesions may appear before, during, or after the gastrointestinal manifestations of CD. (See  <a class="medical medical_review" href="/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Metastatic Crohn disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hidradenitis suppurativa</strong> is a chronic inflammatory skin condition characterized by painful, deep-seated, inflamed nodules that occur primarily in the axillae and inguinal areas. Multiple studies suggest an association with IBD and, particularly, CD [<a href="#rid43">43</a>]. There is a strong female predominance. Most data on hidradenitis suppurativa and IBD are in adults, but case series have also described this combination in adolescents [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7605.html" rel="external">"Hidradenitis suppurativa: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psoriasis</strong>, an immune-mediated inflammatory condition of the skin, is significantly associated with IBD. A meta-analysis notes 3.6 percent prevalence of psoriasis among CD and 2.8 percent in UC [<a href="#rid45">45</a>]. One study suggests that patients with psoriasis have a fourfold increased risk for the development of CD, suggesting that the psoriasis often precedes development of CD [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Psoriasis'</a>.)</p><p></p><p class="bulletIndent1">Certain psoriatic medications may induce or worsen IBD. Conversely, psoriasiform eruption is a known adverse effect of anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy, occurring in over 10 percent of children with IBD who are treated with these drugs [<a href="#rid47">47,48</a>]. Withdrawal of systemic corticosteroids used in IBD can sometimes cause a rebound in psoriasiform lesions [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/120380.html" rel="external">"Medical therapies for Crohn disease in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Psoriatic skin lesions'</a>.)</p><p></p><p class="headingAnchor" id="H2233962277"><span class="h2">Mouth</span><span class="headingEndMark"> — </span>A variety of oral lesions are associated with IBD  (<a class="graphic graphic_picture graphicRef138273" href="/d/graphic/138273.html" rel="external">picture 3</a>) [<a href="#rid50">50,51</a>]. The most common is aphthous stomatitis (superficial ulcerations), which occurs in approximately 10 percent of children with IBD [<a href="#rid24">24,35,36,38</a>] and is approximately three times more common among those with CD compared with UC [<a href="#rid38">38</a>]. As an example, among 48 children who were rigorously evaluated by a dentist, the following oral lesions were identified [<a href="#rid22">22,51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mucogingivitis (12 patients)  (<a class="graphic graphic_picture graphicRef56573" href="/d/graphic/56573.html" rel="external">picture 7</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal tags (4 patients)  (<a class="graphic graphic_picture graphicRef70350" href="/d/graphic/70350.html" rel="external">picture 8</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Deep ulceration (4 patients)  (<a class="graphic graphic_picture graphicRef138812" href="/d/graphic/138812.html" rel="external">picture 9</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Cobblestoning (3 patients)  (<a class="graphic graphic_picture graphicRef71733" href="/d/graphic/71733.html" rel="external">picture 10</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Lip swelling (3 patients)  (<a class="graphic graphic_picture graphicRef58499" href="/d/graphic/58499.html" rel="external">picture 11</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pyostomatitis vegetans (1 patient)</p><p></p><p>Pyostomatitis vegetans is an uncommon oral manifestation of IBD (primarily in UC); it is characterized by multiple small pustules and erosions on the oral mucosa [<a href="#rid50">50</a>].</p><p>These oral manifestations tend to correlate with intestinal disease activity and respond to treatments for the intestinal disease [<a href="#rid50">50</a>]. Adjunctive therapy in acute or unresponsive cases may include topical glucocorticoids. (See <a class="local">'Oral and perianal disease'</a> above.)</p><p>Medications used for IBD occasionally cause oral lesions, including nonspecific erythema (<a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, thiopurines) and oral lichenoid reactions (<a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> and biologic agents) [<a href="#rid50">50</a>]. Other more severe reactions that require drug cessation are erythema multiforme (many drugs) and Stevens-Johnson syndrome.</p><p class="headingAnchor" id="H3409092626"><span class="h2">Eyes</span><span class="headingEndMark"> — </span>Episcleritis/scleritis occurs in 2 to 5 percent of patients with IBD [<a href="#rid35">35,36,52</a>]. Affected patients may be asymptomatic or complain of burning and itching. Injection of the ciliary vessels and inflammation of the episcleral tissues are the prominent features on physical examination  (<a class="graphic graphic_picture graphicRef67740" href="/d/graphic/67740.html" rel="external">picture 12</a>).</p><p>Uveitis is less common than episcleritis, occurring in 0.5 to 3.0 percent of patients with IBD [<a href="#rid53">53</a>]. However, its consequences are often more severe. The uveitis is frequently bilateral, posterior to the lens, insidious in onset, chronic in duration, and more common in females than males [<a href="#rid54">54</a>]. "Iritis" is an alternate term for anterior uveitis. (See  <a class="medical medical_review" href="/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Ocular disease'</a>.)</p><p>Cataracts may develop in patients with IBD who are chronically treated with glucocorticoids. (See  <a class="medical medical_review" href="/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Rare ocular diseases'</a>.)</p><p class="headingAnchor" id="H2118716670"><span class="h2">Aminotransferase elevations</span><span class="headingEndMark"> — </span>Nonspecific mild elevations of serum aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) are common and often caused by medications or hepatic steatosis [<a href="#rid55">55,56</a>]. IBD medications that may contribute to liver injury include <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, thiopurines (<a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">mercaptopurine</a> or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>), <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid57">57</a>].</p><p>Aminotransferase elevations also may be caused by specific disorders associated with IBD: Individuals with CD have an increased risk for cholelithiasis, but this is uncommon in UC [<a href="#rid57">57-59</a>]. Patients with IBD also have an increased risk for autoimmune hepatitis [<a href="#rid57">57,60-62</a>]. (See  <a class="medical medical_review" href="/d/html/4074.html" rel="external">"Overview of hepatobiliary disorders in patients with inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2157948654"><span class="h2">Sclerosing cholangitis</span><span class="headingEndMark"> — </span>The most significant immunologic liver disease associated with IBD is sclerosing cholangitis (SC), a condition that causes inflammation and scarring of the bile ducts and progresses to complicated hepatobiliary disease, including cholangitis, hepatic cirrhosis, and liver failure [<a href="#rid61">61</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and clinical presentation</strong> – SC occurs in 2 to 10 percent of patients with UC and a smaller proportion of patients with Crohn colitis [<a href="#rid35">35,38,57,61,63</a>]. Patients with SC may present with fatigue, pruritus, and intermittent jaundice; the severity of the SC is not correlated with the colitis disease activity. Between 30 and 70 percent of IBD patients with SC have concurrent clinical, biochemical, and histologic findings of autoimmune hepatitis, in addition to cholangiographic findings consistent with SC; this combination of features is known as autoimmune SC (ASC) or SC-autoimmune hepatitis overlap syndrome [<a href="#rid57">57,64,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and evaluation</strong> – Patients with IBD should undergo laboratory screening for hepatobiliary disease at diagnosis and periodically thereafter. SC is characterized by an elevation of gamma-glutamyl transpeptidase (GGTP) and alkaline phosphatase and a less pronounced elevation of ALT and AST. Patients with marked and persistent liver enzyme elevations (especially of GGTP) should be further evaluated for SC using radiographic imaging (ultrasound, magnetic resonance cholangiopancreatography [MRCP]), and liver biopsy. The liver biopsy evaluates for small-duct SC and autoimmune hepatitis, while the MRCP identifies large duct (hepatic duct, common bile duct disease). Improvements in MRCP quality have resulted in a reduction in use of diagnostic endoscopic retrograde cholangiopancreatography (ERCP), though ERCP may be needed if MRCP is equivocal of if therapeutic intervention is needed for bile duct stricture.</p><p></p><p class="bulletIndent1">Autoimmune markers (antinuclear antibodies [ANA], anti-smooth muscle antibodies [ASMA], antimitochondrial antibodies, and anti-liver-kidney microsomal antibodies) and total immunoglobulin G (IgG) should be measured to evaluate for the possibility of associated autoimmune hepatitis  (<a class="graphic graphic_table graphicRef65135" href="/d/graphic/65135.html" rel="external">table 4</a>) [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – SC is diagnosed based on evidence of cholestasis (elevated GGTP) with characteristic findings on MRCP or ERCP (multifocal stricturing and segmental dilations of the biliary tree, indicating large-duct SC) and/or liver biopsy (periductal concentric fibrosis, fibro-obliterative cholangitis, or primary ductular involvement, without large duct involvement, indicating small-duct SC) [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">The ASC subtype is diagnosed based on the presence of autoimmune markers (primarily ANA and ASMA and, sometimes, perinuclear antineutrophil cytoplasmic autoantibodies), in combination with the above evidence of bile duct damage and hepatitis. The histology of autoimmune hepatitis includes features such as interface hepatitis (with lymphocytes, eosinophils, or plasma cells), periportal hepatocyte necrosis, and varying degrees of fibrosis [<a href="#rid67">67</a>]. Scoring criteria for diagnosing ASC and autoimmune hepatitis in children have been proposed [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment of SC is mainly supportive and palliative; no therapy has been shown to alter the natural history of the disease [<a href="#rid57">57,68,69</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with ASC (ie, with SC associated autoimmune liver disease) should be treated for that disorder, which typically includes glucocorticoid induction followed by maintenance thiopurine [<a href="#rid66">66</a>]. This may be identical to or overlap with the treatment selected for the underlying IBD. (See  <a class="medical medical_review" href="/d/html/3659.html" rel="external">"Management of autoimmune hepatitis", section on 'Pediatric patients'</a> and  <a class="medical medical_review" href="/d/html/3636.html" rel="external">"Autoimmune hepatitis variants: Definitions and treatment", section on 'Autoimmune hepatitis-PSC overlap'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with <a class="drug drug_general" data-topicid="10033" href="/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> (UCDA) has been associated with improvement of laboratory markers of hepatic inflammation and cholestasis [<a href="#rid65">65,70</a>]. In our practice, we routinely utilize UDCA in a dose of approximately 15 mg/kg/day, in two divided doses. However, it should be noted that a causal effect has not been established and spontaneous improvement in laboratory parameters is common [<a href="#rid68">68,71</a>]. Moreover, higher-dose treatment with UCDA (28 to 30 mg/kg/day) may be detrimental [<a href="#rid72">72</a>]. Immunosuppressive medications may improve the underlying IBD but do not alter the course of SC.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> has also been utilized to treat pediatric SC, with some positive outcomes in small observational studies [<a href="#rid73">73-75</a>], but was not effective in another observational study with propensity-score matching [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1">Management of SC in adults is discussed separately. (See  <a class="medical medical_review" href="/d/html/661.html" rel="external">"Primary sclerosing cholangitis in adults: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – In a multinational study that included more than 500 children with IBD-associated SC with five-year follow-up, 21 percent developed portal hypertensive complications (eg, esophageal varices or ascites), 12 percent developed biliary complications (cholangitis with stricture requiring dilatation), and 11 percent progressed to liver transplantation or death [<a href="#rid64">64</a>]. These outcomes were somewhat better than for children with SC that was not associated with IBD. In a smaller single-center study with five-year follow-up (n = 55), 22 percent developed splenomegaly but none had portal hypertension complications, only 4 percent developed biliary complications, and none progressed to liver transplantation or death [<a href="#rid65">65</a>]. By 10 years (n = 16), 12 percent had progressed to transplantation or death. The relatively low rate of complications in this series may have been related to earlier identification of affected patients and/or management strategies, which included routine use of UCDA and treatment for associated autoimmune liver disease, when present.</p><p></p><p class="bulletIndent1">SC is associated with a substantial risk for hepatobiliary cancer (cholangiocarcinoma). In the multinational study cited above, cholangiocarcinoma developed in eight patients (1 percent of pediatric patients with SC with or without IBD); these cases presented at a median of six years after the SC diagnosis, and all were between ages 15 and 18 years and had a biliary stricture that required dilation [<a href="#rid64">64</a>]. Surveillance for cholangiocarcinoma has not been established for pediatric patients. (See  <a class="medical medical_review" href="/d/html/661.html" rel="external">"Primary sclerosing cholangitis in adults: Management", section on 'Gallbladder carcinoma and cholangiocarcinoma'</a>.)</p><p></p><p class="bulletIndent1">In addition, individuals with UC and SC also appear to be at higher risk for developing colorectal cancer compared with patients with UC alone. Therefore, early initiation and frequent surveillance ileocolonoscopy is recommended for patients with SC [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/4055.html" rel="external">"Primary sclerosing cholangitis: Inflammatory bowel disease and colorectal cancer"</a> and  <a class="medical medical_review" href="/d/html/661.html" rel="external">"Primary sclerosing cholangitis in adults: Management", section on 'Colon cancer'</a>.)</p><p></p><p class="headingAnchor" id="H3001615455"><span class="h2">Joints</span><span class="headingEndMark"> — </span>Approximately 4 percent of patients with IBD have arthritis within the first few years after diagnosis, and up to 20 percent have arthralgias, which may present before the gastrointestinal symptoms [<a href="#rid36">36,38,77</a>]. Arthritis is approximately twice as common in CD compared with UC but is more common in patients with Crohn colitis compared with those with gastroduodenal CD [<a href="#rid38">38,78,79</a>]. The arthritis typically is nonerosive and asymmetric, affects large joints (including the hips, knees, and wrists), and parallels the activity of the intestinal involvement [<a href="#rid35">35,78,80</a>]. In contrast, axial skeletal involvement, in the form of ankylosing spondylitis and sacroiliac joint arthritis, is less common and may follow an independent course [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/7787.html" rel="external">"Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases"</a>.)</p><p>Chronic recurrent multifocal osteomyelitis is a rare complication of both CD and UC [<a href="#rid81">81-83</a>]. (See  <a class="medical medical_review" href="/d/html/118084.html" rel="external">"Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO)"</a>.)</p><p class="headingAnchor" id="H905120971"><span class="h2">Venous thromboembolism</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and risk factors</strong> – Active IBD is associated with an increased risk for venous thromboembolism (VTE), which occurs in 1 to 2 percent of hospitalized patients and occasionally includes pulmonary embolism and cerebrovascular events [<a href="#rid84">84-89</a>]. Factors that further increase the risk for VTE include the presence of a central venous catheter, severe disease activity, older age, <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a>, oral contraceptives, and underlying inherited thrombophilia; the risk is generally higher for patients with active UC compared with active CD [<a href="#rid90">90</a>]. In an observational study, 1 percent of hospitalized patients developed VTE, with increased risks for those who were undergoing major surgery (odds ratio [OR] 1.98, 95% CI 1.54-2.55) or having an underlying hypercoagulable diagnosis (OR 7.39, 95% CI 5.34-10.20) [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">In one case series, the most common locations for VTEs were in the cerebral sinuses or lower extremities [<a href="#rid89">89</a>]. Portal vein thrombosis is a rare but potentially life-threatening thrombotic complication, which may present with an acute abdomen or abdominal distension due to ileus [<a href="#rid57">57</a>]. Hepatic vein thrombosis (Budd-Chiari syndrome) also has been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of VTE</strong> – For patients who develop VTE, anticoagulation (eg, low molecular weight heparin) is feasible and appropriate, even in the context of gastrointestinal bleeding [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/4344.html" rel="external">"Pulmonary complications of inflammatory bowel disease", section on 'Prophylaxis for venous thromboembolism'</a> and  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of VTE</strong> – All hospitalized children with IBD should be treated with nonpharmacologic measures to minimize the risk for VTE, including adequate hydration, mobilization, and use of compression stockings or pneumatic devices if appropriate.</p><p></p><p class="bulletIndent1">In addition to nonpharmacologic measures, we suggest prophylactic anticoagulation for any hospitalized child with severe IBD activity and a prior history of thrombosis, consistent with Canadian and European guidelines [<a href="#rid91">91,92</a>]. Prophylactic anticoagulation therapy should be seriously considered for older children (&gt;12 years) with severe IBD activity and other risk factors, including the presence of a central venous line, a family history of VTE, plans to undergo major surgery, or immobility [<a href="#rid84">84,86,92,93</a>]. For patients who have moderate or severe gastrointestinal bleeding, mechanical methods of thromboprophylaxis are preferred, based on recommendations for adults with IBD [<a href="#rid93">93,94</a>]. Drug selection and dosing are discussed separately. (See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"</a>.)</p><p></p><p class="bulletIndent1">Primary prophylaxis is generally recommended for adult IBD patients with severe disease activity and additional risk factors for VTE, such as a central venous catheter and/or a strong family history of VTE [<a href="#rid95">95</a>]. For pediatric patients, the risk of primary VTE is probably somewhat lower than in adults, but the consequences can be serious. In a retrospective study in hospitalized children with IBD and central venous catheters, the rate of thromboembolic complications was lower in patients who received anticoagulant prophylaxis (0 of 24 hospitalizations) compared with patients who were not treated with prophylaxis (5 of 23 hospitalizations; 22 percent) [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/4344.html" rel="external">"Pulmonary complications of inflammatory bowel disease", section on 'Prophylaxis for venous thromboembolism'</a>.)</p><p></p><p class="headingAnchor" id="H24605762"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other complications of IBD include:</p><p class="bulletIndent1"><span class="glyph">●</span>Osteopenia – May be caused by malnutrition, inflammation, pubertal delays, vitamin D deficiency, or treatment with glucocorticoids [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Bone mineral density'</a> and  <a class="medical medical_review" href="/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney stones – Due to malabsorption of calcium and increased absorption of oxalate. (See  <a class="medical medical_review" href="/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gallstones – Due to bile acid malabsorption. (See  <a class="medical medical_review" href="/d/html/4074.html" rel="external">"Overview of hepatobiliary disorders in patients with inflammatory bowel disease", section on 'Gallstones'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatitis – Caused by disease-related inflammation near the pancreatic duct or medication-related (eg, aminosalicylates or thiopurines). (See  <a class="medical medical_review" href="/d/html/5895.html" rel="external">"Causes and contributing risk factors for chronic pancreatitis in children and adolescents", section on 'Obstructive'</a> and  <a class="medical medical_review" href="/d/html/120380.html" rel="external">"Medical therapies for Crohn disease in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genital inflammation – In CD, granulomatous inflammation occasionally affects the vulva [<a href="#rid97">97</a>] or penis and scrotum [<a href="#rid98">98,99</a>] and is independent of fistulizing disease. (See  <a class="medical medical_review" href="/d/html/128406.html" rel="external">"Vulvar lesions: Differential diagnosis of red lesions", section on 'Crohn disease'</a>.)</p><p></p><p>Granulomatous inflammation of other areas, including the lymph nodes and lungs  (<a class="graphic graphic_diagnosticimage graphicRef70948" href="/d/graphic/70948.html" rel="external">image 1</a>), also may be seen in individuals with CD [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/d/html/4344.html" rel="external">"Pulmonary complications of inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H3216609030"><span class="h1">PSYCHOSOCIAL</span><span class="headingEndMark"> — </span>Children and adolescents with any chronic disease, including Crohn disease (CD), are at risk for the development of a variety of psychosocial problems, including depression and anxiety. These problems can interfere with their ability to participate in their normal activities and can also interfere with the medical management of their disease [<a href="#rid101">101-103</a>]. Patients with CD who are suffering from untreated and/or unrecognized depression and anxiety are at increased risk for higher health cost, hospitalization, and disease flares. (See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Psychological screening and support'</a>.)</p><p class="headingAnchor" id="H2001771728"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113229.html" rel="external">"Society guideline links: Inflammatory bowel disease in children"</a>.)</p><p class="headingAnchor" id="H4181673993"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86454.html" rel="external">"Patient education: Crohn disease in children (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/2004.html" rel="external">"Patient education: Crohn disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H8070511"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of inflammatory bowel disease (IBD)</strong> – IBD is comprised of two major categories: Crohn disease (CD) and ulcerative colitis (UC). CD can involve any component of the gastrointestinal tract from the oral cavity to the anus. In contrast, UC is generally limited to the colon, although mild inflammation of the terminal ileum and upper gastrointestinal tract can be also seen in UC. (See <a class="local">'Gastrointestinal manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presenting symptoms</strong> – Patients with IBD typically present in late childhood or adolescence with abdominal pain, weight loss, diarrhea, and hematochezia. Some patients have systemic symptoms including weight loss, fever, and fatigue. Growth failure is often present but may be subtle and not recognized by the patient or family. (See <a class="local">'Presenting symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral and perianal disease</strong> – Oral and perianal disease occurs in approximately one-third of patients with CD; it is not a feature of UC:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant perianal disease, including perianal fistulae or abscesses, occurs in approximately 30 percent of children and adolescents with CD. A highly destructive form of perianal disease occurs in approximately 5 percent of patients. More minor manifestations of perianal disease include anal fissures and skin tags  (<a class="graphic graphic_picture graphicRef121947" href="/d/graphic/121947.html" rel="external">picture 1</a>). (See <a class="local">'Oral and perianal disease'</a> above and  <a class="medical medical_review" href="/d/html/4082.html" rel="external">"Perianal Crohn disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral lesions occur in up to 40 percent of children with CD and may include mucogingivitis, aphthous ulcers, or swelling. Occasionally, oral and perianal disease occurs in the absence of significant intestinal disease. (See <a class="local">'Oral and perianal disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth failure</strong> – Growth failure is present in approximately 30 percent of children and adolescents with CD and is less common in children with UC. It is caused by a combination of anorexia and increased energy needs, related to inflammation. It is often heralded by diminishing height velocity and is best assessed by serial measurements of height, compared with previous height velocity and expected height velocity for age  (<a class="graphic graphic_figure graphicRef70382" href="/d/graphic/70382.html" rel="external">figure 2</a>). (See <a class="local">'Growth failure'</a> above and  <a class="medical medical_review" href="/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extraintestinal manifestations</strong> – Extraintestinal manifestations are sometimes seen in either CD or UC. They may involve the skin, joints, hepatobiliary, eye, and respiratory systems  (<a class="graphic graphic_table graphicRef81867 graphicRef88092" href="/d/graphic/81867.html" rel="external">table 3A-B</a>). These disorders appear idiosyncratically in some patients and not others but are more often associated with colonic disease. The presence or severity of extraintestinal manifestations do not consistently correlate with the degree of intestinal inflammation. This is particularly true for liver disease. (See <a class="local">'Extraintestinal manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sclerosing cholangitis (SC)</strong> – The most serious liver disease associated with IBD is SC, a condition causing inflammation and scarring of the bile ducts, which may lead to complicated hepatobiliary disease, including cholangitis, hepatic cirrhosis, and liver failure, as well as risk for hepatobiliary cancer. SC occurs in up to 10 percent of patients with UC and a smaller proportion of patients with Crohn colitis and is often associated with concomitant autoimmune hepatitis. Patients with IBD should undergo laboratory screening for hepatobiliary disease at diagnosis and periodically thereafter. Those with abnormal results should undergo a full evaluation for SC and the possibility of associated autoimmune hepatitis. (See <a class="local">'Sclerosing cholangitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Venous thromboembolism (VTE)</strong> – Active IBD is associated with an increased risk for VTE, which occurs in up to 2 percent of hospitalized patients and can have life-threatening consequences. Nonpharmacologic interventions to minimize the risk of thromboembolism should be used for all hospitalized children with IBD, including adequate hydration, mobilization, and use of compression stockings or pneumatic devices if appropriate.</p><p></p><p class="bulletIndent2">For any hospitalized child with severe IBD activity and a prior history of thromboembolism, we suggest prophylactic anticoagulation therapy, provided that gastrointestinal bleeding is not moderate or severe (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also suggest prophylactic anticoagulation therapy for older children (&gt;12 years) with the combination of severe IBD activity and other risk factors, including the presence of a central venous line, family history of thromboembolism, or immobility (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Venous thromboembolism'</a> above.)</p><p></p><p class="headingAnchor" id="H253505125"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Tyler Burpee, MD, Alan Leichtner, MD, George H Russell, MD, MS, and Mala Setty, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Mendeloff AI, Calkins BM. The epidemiology of idiopathic inflammatory bowel disease. In: Inflammatory Bowel Disease, Kirsner JB, Shorter RG (Eds), Lea &amp; Febiger, Philadelphia 1988. p.3.</li><li><a class="nounderline abstract_t">Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis 2008; 14 Suppl 2:S4.</a></li><li><a class="nounderline abstract_t">Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17:423.</a></li><li><a class="nounderline abstract_t">Müller KE, Lakatos PL, Arató A, et al. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 57:576.</a></li><li><a class="nounderline abstract_t">Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013; 58:519.</a></li><li><a class="nounderline abstract_t">Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151:523.</a></li><li><a class="nounderline abstract_t">Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105:681.</a></li><li><a class="nounderline abstract_t">Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.</a></li><li><a class="nounderline abstract_t">Gupta N, Bostrom AG, Kirschner BS, et al. Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am J Gastroenterol 2008; 103:2092.</a></li><li><a class="nounderline abstract_t">Queliza K, Ihekweazu FD, Schady D, et al. Granulomatous Upper Gastrointestinal Inflammation in Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2018; 66:620.</a></li><li><a class="nounderline abstract_t">Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5A.</a></li><li><a class="nounderline abstract_t">Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17:1314.</a></li><li><a class="nounderline abstract_t">Gupta N, Bostrom AG, Kirschner BS, et al. Incidence of stricturing and penetrating complications of Crohn's disease diagnosed in pediatric patients. Inflamm Bowel Dis 2010; 16:638.</a></li><li><a class="nounderline abstract_t">Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101:360.</a></li><li><a class="nounderline abstract_t">Pfefferkorn MD, Marshalleck FE, Saeed SA, et al. NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula. J Pediatr Gastroenterol Nutr 2013; 57:394.</a></li><li><a class="nounderline abstract_t">Schaefer ME, Machan JT, Kawatu D, et al. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2010; 8:789.</a></li><li><a class="nounderline abstract_t">Markowitz J, Grancher K, Rosa J, et al. Highly destructive perianal disease in children with Crohn's disease. J Pediatr Gastroenterol Nutr 1995; 21:149.</a></li><li><a class="nounderline abstract_t">Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. Inflamm Bowel Dis 2009; 15:383.</a></li><li><a class="nounderline abstract_t">Wong S, Lemberg DA, Day AS. Exclusive enteral nutrition in the management of perianal Crohn's disease in children. J Dig Dis 2010; 11:185.</a></li><li><a class="nounderline abstract_t">Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. Am J Gastroenterol 2020; 115:1812.</a></li><li><a class="nounderline abstract_t">Tolia V. Perianal Crohn's disease in children and adolescents. Am J Gastroenterol 1996; 91:922.</a></li><li><a class="nounderline abstract_t">Harty S, Fleming P, Rowland M, et al. A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886.</a></li><li><a class="nounderline abstract_t">Pittock S, Drumm B, Fleming P, et al. The oral cavity in Crohn's disease. J Pediatr 2001; 138:767.</a></li><li><a class="nounderline abstract_t">Galbraith SS, Drolet BA, Kugathasan S, et al. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 2005; 116:e439.</a></li><li><a class="nounderline abstract_t">Ammoury RF, Pfefferkorn MD. Significance of esophageal Crohn disease in children. J Pediatr Gastroenterol Nutr 2011; 52:291.</a></li><li><a class="nounderline abstract_t">Ramaswamy K, Jacobson K, Jevon G, Israel D. Esophageal Crohn disease in children: a clinical spectrum. J Pediatr Gastroenterol Nutr 2003; 36:454.</a></li><li><a class="nounderline abstract_t">Splawski J, Aktay AN, Perry S, et al. Differences in Clinical Presentation of Eosinophilic Esophagitis in Pediatric Patients With Ulcerative Colitis and Crohn Disease. J Pediatr Gastroenterol Nutr 2022; 75:76.</a></li><li><a class="nounderline abstract_t">Moore H, Wechsler J, Frost C, et al. Comorbid Diagnosis of Eosinophilic Esophagitis and Inflammatory Bowel Disease in the Pediatric Population. J Pediatr Gastroenterol Nutr 2021; 72:398.</a></li><li><a class="nounderline abstract_t">Sonnenberg A, Turner KO, Genta RM. Comorbid Occurrence of Eosinophilic Esophagitis and Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021; 19:613.</a></li><li><a class="nounderline abstract_t">Paerregaard A, Uldall Urne F. Anthropometry at the time of diagnosis in Danish children with inflammatory bowel disease. Acta Paediatr 2005; 94:1682.</a></li><li><a class="nounderline abstract_t">Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88:995.</a></li><li><a class="nounderline abstract_t">Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010; 105:1893.</a></li><li><a class="nounderline abstract_t">Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics 2007; 120:e1418.</a></li><li><a class="nounderline abstract_t">Ricciuto A, Mack DR, Huynh HQ, et al. Diagnostic Delay Is Associated With Complicated Disease and Growth Impairment in Paediatric Crohn's Disease. J Crohns Colitis 2021; 15:419.</a></li><li><a class="nounderline abstract_t">Greuter T, Bertoldo F, Rechner R, et al. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment. J Pediatr Gastroenterol Nutr 2017; 65:200.</a></li><li><a class="nounderline abstract_t">Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:63.</a></li><li><a class="nounderline abstract_t">Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008; 87:281.</a></li><li><a class="nounderline abstract_t">Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010; 51:140.</a></li><li><a class="nounderline abstract_t">Dinulos JG, Darmstadt GL, Len MK, et al. Infantile Crohn disease presenting with diarrhea and pyoderma gangrenosum. Pediatr Dermatol 2006; 23:43.</a></li><li><a class="nounderline abstract_t">Schneider SL, Foster K, Patel D, Shwayder T. Cutaneous manifestations of metastatic Crohn's disease. Pediatr Dermatol 2018; 35:566.</a></li><li><a class="nounderline abstract_t">Dederichs F, Iesalnieks I, Sladek M, et al. Genital Granulomatosis in Male and Female Patients With Crohn's Disease: Clinical Presentation and Treatment Outcomes. J Crohns Colitis 2018; 12:197.</a></li><li><a class="nounderline abstract_t">Qian Y, He W, Zheng CY, et al. Significance of granuloma and granulomatous lymphangitis in the differential diagnosis of Crohn's disease. J Dig Dis 2020; 21:454.</a></li><li><a class="nounderline abstract_t">Chen WT, Chi CC. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol 2019; 155:1022.</a></li><li><a class="nounderline abstract_t">Natarajan B, Sauer C, Shehata B, Kugathasan S. Hidradenitis suppurativa and pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2015; 60:e29.</a></li><li><a class="nounderline abstract_t">Alinaghi F, Tekin HG, Burisch J, et al. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis 2020; 14:351.</a></li><li><a class="nounderline abstract_t">Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2013; 72:1200.</a></li><li><a class="nounderline abstract_t">Eickstaedt JB, Killpack L, Tung J, et al. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Pediatr Dermatol 2017; 34:253.</a></li><li><a class="nounderline abstract_t">Courbette O, Aupiais C, Viala J, et al. Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019; 69:189.</a></li><li><a class="nounderline abstract_t">Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2018; 78:383.</a></li><li><a class="nounderline abstract_t">Shazib MA, Byrd KM, Gulati AS. Diagnosis and Management of Oral Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2022; 74:7.</a></li><li><a class="nounderline abstract_t">Favia G, Limongelli L, Tempesta A, et al. Oral lesions as first clinical manifestations of Crohn's disease in paediatric patients: a report on 8 cases. Eur J Paediatr Dent 2020; 21:66.</a></li><li><a class="nounderline abstract_t">Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982; 14:356.</a></li><li><a class="nounderline abstract_t">Naviglio S, Parentin F, Nider S, et al. Ocular Involvement in Children with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23:986.</a></li><li><a class="nounderline abstract_t">Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997; 115:61.</a></li><li><a class="nounderline abstract_t">Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102:344.</a></li><li><a class="nounderline abstract_t">Pusateri AJ, Kim SC, Dotson JL, et al. Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2015; 60:592.</a></li><li><a class="nounderline abstract_t">Saubermann LJ, Deneau M, Falcone RA, et al. Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees. J Pediatr Gastroenterol Nutr 2017; 64:639.</a></li><li><a class="nounderline abstract_t">Lorusso D, Leo S, Mossa A, et al. Cholelithiasis in inflammatory bowel disease. A case-control study. Dis Colon Rectum 1990; 33:791.</a></li><li><a class="nounderline abstract_t">Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45:1267.</a></li><li><a class="nounderline abstract_t">Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14:325.</a></li><li><a class="nounderline abstract_t">Deneau M, Jensen MK, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013; 58:1392.</a></li><li><a class="nounderline abstract_t">Bramuzzo M, Martelossi S, Torre G, et al. Clinical Features and Risk Factors of Autoimmune Liver Involvement in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016; 63:259.</a></li><li><a class="nounderline abstract_t">Chandrakumar A, Loeppky R, Deneau M, El-Matary W. Inflammatory Bowel Disease in Children with Elevated Serum Gamma Glutamyltransferase Levels. J Pediatr 2019; 215:144.</a></li><li><a class="nounderline abstract_t">Deneau MR, El-Matary W, Valentino PL, et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology 2017; 66:518.</a></li><li><a class="nounderline abstract_t">Hensel KO, Kyrana E, Hadzic N, et al. Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome. J Pediatr 2021; 238:50.</a></li><li><a class="nounderline abstract_t">Mieli-Vergani G, Vergani D, Baumann U, et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2018; 66:345.</a></li><li><a class="nounderline abstract_t">Geller SA. Autoimmune hepatitis: Histopathology. Clin Liver Dis (Hoboken) 2014; 3:19.</a></li><li><a class="nounderline abstract_t">Deneau MR, Mack C, Mogul D, et al. Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis. Hepatology 2021; 73:1061.</a></li><li><a class="nounderline abstract_t">Saffioti F, Gurusamy KS, Hawkins N, et al. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017; 3:CD011343.</a></li><li><a class="nounderline abstract_t">Gilger MA, Gann ME, Opekun AR, Gleason WA Jr. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr 2000; 31:136.</a></li><li><a class="nounderline abstract_t">Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.</a></li><li><a class="nounderline abstract_t">Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50:808.</a></li><li><a class="nounderline abstract_t">Abarbanel DN, Seki SM, Davies Y, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013; 33:397.</a></li><li><a class="nounderline abstract_t">Damman JL, Rodriguez EA, Ali AH, et al. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther 2018; 47:886.</a></li><li><a class="nounderline abstract_t">Davies YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47:61.</a></li><li><a class="nounderline abstract_t">Oliva S, Thomson M, de Ridder L, et al. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:414.</a></li><li><a class="nounderline abstract_t">Levy R, Amarilyo G, Tal R, et al. Musculoskeletal Manifestations as Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents. J Pediatr 2019; 209:233.</a></li><li class="breakAll">Levine J. Arthropathies and ocular complications of inflammatory bowel disease. In: Inflammatory Bowel Disease: From Bench to Bedside, 1st ed, Targan SR, Shanahan F (Eds), Williams &amp; Wilkins, 1994. p.450.</li><li><a class="nounderline abstract_t">Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children. Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci 1986; 31:492.</a></li><li><a class="nounderline abstract_t">Palm Ø, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001; 40:1256.</a></li><li><a class="nounderline abstract_t">Bousvaros A, Marcon M, Treem W, et al. Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children. Dig Dis Sci 1999; 44:2500.</a></li><li><a class="nounderline abstract_t">Audu GK, Nikaki K, Crespi D, et al. Chronic recurrent multifocal osteomyelitis and inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2015; 60:586.</a></li><li><a class="nounderline abstract_t">Dushnicky MJ, Beattie KA, Cellucci T, et al. Pediatric Patients with a Dual Diagnosis of Inflammatory Bowel Disease and Chronic Recurrent Multifocal Osteomyelitis. J Pediatr Gastroenterol Nutr 2021; 73:626.</a></li><li><a class="nounderline abstract_t">Nylund CM, Goudie A, Garza JM, et al. Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56:485.</a></li><li><a class="nounderline abstract_t">Zitomersky NL, Levine AE, Atkinson BJ, et al. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 57:343.</a></li><li><a class="nounderline abstract_t">Diamond CE, Hennessey C, Meldau J, et al. Catheter-Related Venous Thrombosis in Hospitalized Pediatric Patients with Inflammatory Bowel Disease: Incidence, Characteristics, and Role of Anticoagulant Thromboprophylaxis with Enoxaparin. J Pediatr 2018; 198:53.</a></li><li><a class="nounderline abstract_t">Egberg MD, Galanko JA, Barnes EL, Kappelman MD. Thrombotic and Infectious Risks of Parenteral Nutrition in Hospitalized Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2019; 25:601.</a></li><li><a class="nounderline abstract_t">McKie K, McLoughlin RJ, Hirsh MP, et al. Risk Factors for Venous Thromboembolism in Children and Young Adults With Inflammatory Bowel Disease. J Surg Res 2019; 243:173.</a></li><li><a class="nounderline abstract_t">Aardoom MA, Klomberg RCW, Kemos P, et al. The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry. J Crohns Colitis 2022; 16:695.</a></li><li><a class="nounderline abstract_t">Kuenzig ME, Bitton A, Carroll MW, et al. Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study. J Crohns Colitis 2021; 15:2031.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146:835.</a></li><li><a class="nounderline abstract_t">Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:292.</a></li><li><a class="nounderline abstract_t">Mitchel E, Diamond T, Albenberg L. Venous Thrombosis in Pediatric Inflammatory Bowel Disease. J Pediatr 2020; 216:213.</a></li><li><a class="nounderline abstract_t">Branchford BR, Betensky M, Goldenberg NA. Pediatric issues in thrombosis and hemostasis: The how and why of venous thromboembolism risk stratification in hospitalized children. Thromb Res 2018; 172:190.</a></li><li><a class="nounderline abstract_t">Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.</a></li><li><a class="nounderline abstract_t">Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:1598.</a></li><li><a class="nounderline abstract_t">Shields BE, Richardson C, Arkin L, Kornik R. Vulvar Crohn disease: Diagnostic challenges and approach to therapy. Int J Womens Dermatol 2020; 6:390.</a></li><li><a class="nounderline abstract_t">Motamed F, Esfandiarpour B, Ahmadipour S. Unusual presentation of Crohn's disease in a boy with penile swelling. Clin Case Rep 2018; 6:2396.</a></li><li><a class="nounderline abstract_t">Bhoyrul B, Hilmy M, Lyon C. Crohn's disease of the penis and scrotum: a prospective study. Eur J Gastroenterol Hepatol 2018; 30:1528.</a></li><li><a class="nounderline abstract_t">Krishnan S, Banquet A, Newman L, et al. Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy. Pediatrics 2006; 117:1440.</a></li><li><a class="nounderline abstract_t">Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004; 66:79.</a></li><li><a class="nounderline abstract_t">Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther 2005; 22:101.</a></li><li><a class="nounderline abstract_t">Limsrivilai J, Stidham RW, Govani SM, et al. Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2017; 15:385.</a></li></ol></div><div id="topicVersionRevision">Topic 5865 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mendeloff AI, Calkins BM. The epidemiology of idiopathic inflammatory bowel disease. In: Inflammatory Bowel Disease, Kirsner JB, Shorter RG (Eds), Lea &amp; Febiger, Philadelphia 1988. p.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18816745" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : What is the peak age for onset of IBD?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564651" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23820399" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926499" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961699" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8359640" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Growth failure in children with inflammatory bowel disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3181677" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18796101" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Presentation and disease course in early- compared to later-onset pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28991840" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Granulomatous Upper Gastrointestinal Inflammation in Pediatric Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151544" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21560194" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19760783" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence of stricturing and penetrating complications of Crohn's disease diagnosed in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454844" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23783018" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566311" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Factors that determine risk for surgery in pediatric patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7472900" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Highly destructive perianal disease in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19023863" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Course and treatment of perianal disease in children newly diagnosed with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579222" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Exclusive enteral nutrition in the management of perianal Crohn's disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33156100" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633582" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Perianal Crohn's disease in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234026" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A prospective study of the oral manifestations of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343060" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The oral cavity in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16099852" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150652" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Significance of esophageal Crohn disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12658034" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Esophageal Crohn disease in children: a clinical spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35442240" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Differences in Clinical Presentation of Eosinophilic Esophagitis in Pediatric Patients With Ulcerative Colitis and Crohn Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33230079" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comorbid Diagnosis of Eosinophilic Esophagitis and Inflammatory Bowel Disease in the Pediatric Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32068153" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comorbid Occurrence of Eosinophilic Esophagitis and Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303711" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Anthropometry at the time of diagnosis in Danish children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14612366" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Presenting features of inflammatory bowel disease in Great Britain and Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145606" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nutritional status and growth in pediatric Crohn's disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055660" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Gender differences in presentation and course of disease in pediatric patients with Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32978629" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic Delay Is Associated With Complicated Disease and Growth Impairment in Paediatric Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27801751" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626963" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794711" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453677" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445411" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Infantile Crohn disease presenting with diarrhea and pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29952016" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cutaneous manifestations of metastatic Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029098" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Genital Granulomatosis in Male and Female Patients With Crohn's Disease: Clinical Presentation and Treatment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32621394" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Significance of granuloma and granulomatous lymphangitis in the differential diagnosis of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31290938" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24121140" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hidradenitis suppurativa and pediatric Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504363" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22941766" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28211161" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30921262" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29332708" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34560727" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis and Management of Oral Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32183532" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Oral lesions as first clinical manifestations of Crohn's disease in paediatric patients: a report on 8 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6125121" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ocular manifestations of inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28328621" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ocular Involvement in Children with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006426" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100965" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Abnormal hepatic biochemistries in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25493346" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27984347" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202567" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cholelithiasis in inflammatory bowel disease. A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464998" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1500696" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686586" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26756875" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical Features and Risk Factors of Autoimmune Liver Involvement in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31500861" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Inflammatory Bowel Disease in Children with Elevated Serum Gamma Glutamyltransferase Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28390159" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34303727" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29356770" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31236264" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Autoimmune hepatitis: Histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32946600" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28417463" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10941964" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101749" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnosis and management of primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19585548" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23054338" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29411404" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18607270" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130311" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857776" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Musculoskeletal Manifestations as Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857776" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Musculoskeletal Manifestations as Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3698765" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Arthritis associated with inflammatory bowel disease in children. Relationship of joint disease to activity and severity of bowel lesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709609" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10630504" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25493348" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Chronic recurrent multifocal osteomyelitis and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34238828" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pediatric Patients with a Dual Diagnosis of Inflammatory Bowel Disease and Chronic Recurrent Multifocal Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23232326" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23752078" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29628414" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Catheter-Related Venous Thrombosis in Hospitalized Pediatric Patients with Inflammatory Bowel Disease: Incidence, Characteristics, and Role of Anticoagulant Thromboprophylaxis with Enoxaparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30304444" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Thrombotic and Infectious Risks of Parenteral Nutrition in Hospitalized Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31181463" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Risk Factors for Venous Thromboembolism in Children and Young Adults With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34599822" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34175936" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462530" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30044358" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31610937" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Venous Thrombosis in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29472108" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pediatric issues in thrombosis and hemostasis: The how and why of venous thromboembolism risk stratification in hospitalized children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574271" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20198712" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33898705" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Vulvar Crohn disease: Diagnostic challenges and approach to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30564335" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Unusual presentation of Crohn's disease in a boy with penile swelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30395015" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Crohn's disease of the penis and scrotum: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585347" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747641" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16011668" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27645518" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
